PharmaShots | Incisive News in 3 Shots

Subscribe Now

P-III Study

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

July 16, 2021

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

July 16, 2021

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

March 18, 2021

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

March 18, 2021

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

March 10, 2021

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

March 10, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us